Navigation Links
Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/17/2008

(Staccato loxapine) is being developed for the acute treatment of migraine headaches. AZ-104 is a lower dose version of AZ-004. In March 2008, the Company announced initial results of an in-clinic, multi-center, randomized, double-blind, single administration, placebo-controlled Phase 2a proof-of-concept clinical trial in 168 migraine patients with or without aura. Three doses of AZ-104 (1.25, 2.5 and 5 mg) were evaluated against placebo in the clinical trial. Using the IHS (International Headache Society) 4-point rating scale, the primary efficacy endpoint was pain-relief response at 2 hours post-administration. AZ-104 met the primary efficacy endpoint of the clinical trial for two dose levels of the drug compared to placebo. Statistically significant improvements in pain response were observed in 76.7% of patients at the 5 mg dose (p = 0.02), 79.1% of patients at the 2.5 mg dose (p = 0.01) and 67.4% of patients at the 1.25 mg dose (p = 0.18), compared to 51.3% of patients receiving placebo. Using survival analysis for pain relief response, all three dose groups were statistically superior (p < 0.05) to placebo during the 4-hour post-treatment time period that the patients remained in the clinic. AZ-004 is being developed through Symphony Allegro.

-- AZ-002 (Staccato alprazolam) is being developed for the acute treatment of panic attacks associated with panic disorder. Alexza is conducting a Phase 2a proof-of-concept clinical trial in panic disorder patients. The primary aim of the in-clinic trial is to assess the safety and efficacy of a single dose of AZ-002 in treating a pharmacologically-induced panic attack. Alexza has completed the open-label, lead-in segment of the study, identifying the 1 mg AZ-002 dose as an acceptable dose in terms of safety and efficacy. Alexza expects the enrollment of this clinical trial to be completed in Q2 2008. AZ- 002 is also being developed through Symphony Allegro.

-- AZ-003 (Staccato fentanyl) is being developed
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, ... with patented and proprietary technology used to develop ... bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, ... payment from Abengoa Bioenergy for commercial scale production ... biomass into ethanol, developed under Abengoa,s license agreement ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... provider for the medical industries, announced today the expansion of its ... New York City . genae Americas was incorporated in 2011. ... centered in one of the highest concentrations of medical innovation and ... , President at genae Americas. "The expansion of genae from ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... As part of its ongoing work in the prevention ... Diagnostics is pleased to announce its sponsorship of the ... a kick-off event at Loyola University in Chicago on ... the goal of World MRSA Day is to highlight ...
... 28 Chimerix, Inc., a pharmaceutical company developing orally-available ... and Chief Executive Officer, will present a corporate overview ... 5th, 2010 at 2:00pm PT.  The conference is being ... Mr. Moch will discuss the company,s antiviral ...
Cached Medicine Technology:Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day 2Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day 3Chimerix to Present at 9th Annual BIO Investor Forum 2
(Date:10/1/2014)... study published today in the Journal of the ... than 50 years with moderate or severe chronic knee ... from the University of Melbourne randomly assigned 282 patients ... no acupuncture or sham or pretend laser treatment. ... and acupuncturists blinded to laser and sham (inactive) laser ...
(Date:10/1/2014)... 1, 2014) Despite a policy focus on ... disabilities, this vulnerable population continues to have significant ... The Journal of the American Dental Association , ... Tufts University School of Dental Medicine report on ... at-home oral care provided by caregivers to adults ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining how ... family members. , Life insurance plans provide important financial ... should always carry a life insurance policy as their ... the family. , Clients can choose from several ... coverage or from a permanent policy. No medical exam ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
Breaking Medicine News(10 mins):Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2
... The following is being,issued by Center for Consumer Freedom:, ... preparing,to celebrate time-honored traditions like caroling, tree-trimming, and,leaving cookies ... of trans fat,bans and frivolous lawsuits, serving baked goods ... the receiving end of a very un-merry obesity lawsuit., ...
... Strategic ... Plan, CLEVELAND, Dec. 20 ... Executive Officer,University Hospitals, has agreed to serve as the health system,s leader for,an ... Board of Directors, said, "I join my,Board colleagues in underscoring our support for ...
... Need, NORTH KINGSTOWN, R.I., Dec. 20 On ... of Dominion Diagnostics,joined together in the spirit of the ... RI. The party proved a sight to be seen; ... Ballroom, and,many guests dressed to the nines for the ...
... PICK ONE" ENCOURAGING ... TOGETHER, NEW YORK, Dec. 20 Just in time ... launch of "Kick One, Pick One",(KOPO), the network,s new pro-social ... more time together. Bowing Jan. 1, KOPO is an,on-air, online ...
... groundbreaking experiment published in Cloning & Stem Cells, scientists ... embryonic stem cell lines that open the door for ... an immune reaction in large segments of the population. ... have a simple genetic profile in the critical areas ...
... Vegas business and Oak Ridge National Laboratory are improving the ... heart failure. , The task for ORNL researchers Chuck Britton, ... Noninvasive Medical Technologies ZOE, a medical device that monitors a ... importance to members of the military and to thousands of ...
Cached Medicine News:Health News:Center for Consumer Freedom Releases 'Don't Sue Me Santa' Christmas Cookie Liability Waiver 2Health News:University Hospitals Chief Executive Officer Extends Contract 2Health News:University Hospitals Chief Executive Officer Extends Contract 3Health News:Dominion Diagnostics Supports Rhode Island's Toys for Tots Initiative at Its 2007 Holiday Celebration 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:Human embryonic stem cell lines created that avoid immune rejection 2Health News:Nevada company, ORNL develop potential lifesaver 2
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
A handy quick-reference tool for busy residents and clinicians with key facts and points essential for day-to-day patient care....
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: